Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers; VMS+ software for use in creating three-dimensional model that generates accurate heart volumetric measurements. It also develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pulmonary hypertension, cardiotoxicity of chemotherapy treatments for cancer, and Covid-19 related heart issues. The company was incorporated in 2005 and is headquartered in Toronto, Canada.
Stock data | 2024 | Change |
---|---|---|
Price | $0.135 | N/A |
Market Cap | $21.17M | N/A |
Shares Outstanding | 156.82M | N/A |
Employees | 0 | N/A |